Live Breaking News & Updates on Catherinem Bollard

Stay updated with breaking news from Catherinem bollard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Novel gene-editing strategy harnesses an unusual protective ability to eliminate HIV-1 infection

Genetic alterations that give rise to a rare, fatal disorder known as MOGS-CDG paradoxically also protect cells against infection by viruses. ....

San Francisco , United States , Thomasj Cradick , Conradry Cruz , Shuren Liao , Kamel Khalili , Shohreh Amini , Laurah Carnell , Catherinem Bollard , James Dressman , Chong Liu , Danielle Ellis , Daniellek Sohaii , Magda Florez , Carlos Barrero , Triciah Burdo , Aanand Mehta , Jennifer Gordon , Rafal Kaminski , Stephane Grauzam , Neuroaids Center , Department Of Microbiology , Department Of Cell , School Of Pharmacy , National Institutes Of Health , Temple University ,

Brentuximab in Pediatric HL: 'Paradigm Shift' and Just Approved

Adding brentuximab vedotin to chemotherapy in pediatric Hodgkin lymphoma produced results that have been hailed as a paradigm shift and have just led to FDA approval for this new indication. ....

New York , United States , Emory University School Of Medicine , Sharon Castellino , Kara Kelly , Angelam Feraco , Catherinem Bollard , Mark Roschewski , Blood Disorders Center , National Cancer Institute , Pediatric Hodgkin Consortium , Children Oncology Group , Drug Administration , Winship Cancer Institute Of Emory University , Biomedical Sciences , Baldrick Foundation , George Washington University , Department Of Pediatrics , University At Buffalo , Jacobs School Of Medicine , Oncology Group , Jacobs School , Emory University School , Winship Cancer Institute , Emory University , New England Journal ,

Brentuximab vedotin regimen lowers relapse risk in pediatric high-risk Hodgkin lymphoma

The addition of first-line brentuximab vedotin to chemotherapy reduced risk for relapse compared with standard treatment among pediatric patients with high-risk Hodgkin lymphoma, according to study results. The findings, published in The New England Journal of Medicine, additionally showed the brentuximab vedotin (Adcetris, Seagen) regimen to be well tolerated. ....

Sharonm Castellino , Catherinem Bollard , Mark Roschewski , Blood Disorders Center , Children Oncology Group , Emory University School Of Medicine , National Cancer Trials Network Cooperative Group , Winship Cancer Institute Of Emory University , Cancer Research , Children National Research Institute Center , Immunology Research , New England Journal , Aflac Cancer , Emory University School , Winship Cancer Institute , Emory University , Oncology Group , National Cancer Trials Network Cooperative , National Research Institute ,